<DOC>
	<DOCNO>NCT02795039</DOCNO>
	<brief_summary>The purpose study demonstrate bioequivalence test drug product , fulvestrant Injection , 50 mg/mL , Reference Listed Drug , Faslodex® Injection , 50 mg/mL .</brief_summary>
	<brief_title>Bioequivalence Study Fulvestrant Injection 50 mg/mL Healthy Post-menopausal Female Subjects</brief_title>
	<detailed_description>This study conduct establish bioequivalence sponsor 's test product [ fulvestrant Injection , 50 mg/mL ( Manufactured Fresenius Kabi , USA ) ] reference list drug [ Faslodex® Injection , 50 mg/mL , ( Distributed AstraZeneca Pharmaceuticals , USA ] intramuscular administration 250 mg dose ( 5 mL injection ) upper outer quadrant right buttock normal , healthy , nonsmoking post-menopausal female subject . The order receive test product ( T ) reference list drug ( R ) subject study determine accord randomization schedule . Subjects allocate ratio 1:1 treatment group ( i.e . T R ) .</detailed_description>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Normal , healthy , non smoking postmenopausal female subject age 40 65 year ( inclusive ) Note : Postmenopausal define 12 month spontaneous amenorrhea 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/mL . The amenorrhea due lactation Body Mass Index ( BMI = weight/height2 ) great equal 18.5 kg/m2 less equal 29.9 kg/m2 Physical examination , 12lead electrocardiogram ( ECG ) vital sign without clinically significant finding Negative urine drug abuse screen , urine nicotine ( cotinine ) screen , breath alcohol screen . Negative hepatitis Bsurface antigen , hepatitis C Human Immunodeficiency Virus ( HIV ) Clinical laboratory value within acceptable range , unless deem clinically significant principal investigator subinvestigator . Availability subject entire study period willingness subject adhere protocol requirement evidence sign Informed Consent Form ( ICF ) . History clinically significant gastrointestinal , renal , hepatic , neurologic , hematologic , endocrine , oncologic , pulmonary , immunologic , musculoskeletal , psychiatric , cardiovascular disease malignancy condition , opinion principal investigator subinvestigator , would jeopardize safety subject impact validity study result . A history allergic adverse response ( ) fulvestrant , castor oil , benzyl alcohol , benzyl benzoate , polysorbate 80 , αtocopherol comparable similar product . Smoking use tobacco product within 6 month prior first dose study drug study Positive urine pregnancy test screen serum pregnancy test prior administration study drug . History bleed disorder Consumption alcohol exceed 10 drinks/ week previous 1 year Intolerance to/fear venipuncture , needle blood draw Have consume product undergone procedure mention `` restriction table '' protocol Surgicallyinduced post menopausal female</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>